Daily Stock List
Stragenics, Inc. (ASAB)
SuperStockTips, Penny Stock Finder, Beacon Equity Research, Stock Preacher, Penny Stock Craze, InvestorSoup, and Epic Stock Picks reported earlier on Stragenics, Inc. (ASAB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Stragenics, Inc. is a holding company that operates recreational cannabis consumer Websites. The Company lists on the OTC Markets Group’s OTCQB. The Company was formerly known as Allerayde SAB, Inc. It changed its name to Stragenics, Inc. in April 2014. Stragenics earlier completed the acquisition of BakedAmerican.com. This acquisition launches Stragenics’ new Media Business Group. BakedAmerican is a recreational cannabis consumer website. The site provides product information, dispensary locations, strain information, and resources for marijuana legal states. Stragenics has its corporate headquarters in Melbourne, Florida.
Stragenics operates bakedamerican.com, bakedamerican.org, bakedamerica.com, and bakedamerica.org, which enable customers to identify, rate, and explore legal marijuana dispensaries, and also compare experiences and products. In addition, the Company operates bakedamericantv.com and bakedamerican.tv. These provide news feeds for marijuana related information focused on national developments, impact on state legislation, as well as new trends and legislation.
This first new acquisition for Stragenics is in line with the Company’s strategy of engaging in the building of shareholder value by way of both acquisitions and internal business development of, or investment in, small public and private technology companies entering their commercialization stage.
BakedAmerican projects for the future include an on-line video resource channel featuring original content. Future projects additionally include a new forum site where users will be able to share information, ideas, and practical solutions to issues discussed in many threads.
BakedAmerican.com will allow consumers to identify, rate, and explore legal marijuana dispensaries and compare experiences and products. Through RSS information sources, the news channel provides news feeds for marijuana related information centered on nationally important developments, impact on state legislation, new trends, and new legislation.
The alpha version of the site (based on prior survey results) is undergoing new expanded development and new testing, while implementing the independent survey suggestions. Furthermore, the development team is incorporating data sources to populate the site's Dispensaries and Strains sections. Stragenics intention is to market its website through extensive Internet Marketing, direct marketing and sales.
Stragenics plans to generate revenue chiefly through the sale of online display advertising on its website to businesses local to the areas it covers, initially the Colorado and Washington state geographies, and also developing a marketing program for sector business entities to have the opportunity to place themselves prominently within the BakedAmerican local directory for increased visibility.
Stragenics, Inc. (ASAB), closed Thursday's trading session at $0.038, up 11.76%, on 440,340 volume with 46 trades. The average volume for the last 60 days is 144,472 and the stock's 52-week low/high is $0.0206/$0.25.
Ecrypt Technologies, Inc. (ECRY)
Greenbackers reported this week on Ecrypt Technologies, Inc. (ECRY), OTCtipReporter, PennyStockScholar, PennyTrader, Smallcap Investment did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Ecrypt Technologies, Inc. is a high technology security solutions portfolio provider. The Company assists corporate entities, governments, and individuals to protect their organizations against physical and cyber-attacks through its offering of the most technically-advanced, cost-effective and reliable software, tools and systems. Ecrypt’s main product includes Ecrypt One. This is an email server with integrated security technology used to protect email and attachments in transit and at rest. Ecrypt Technologies is headquartered in Austin, Texas and the Company lists on the OTC Bulletin Board.
Essentially, Ecrypt markets and distributes proprietary and allied security, and also defense and information security software, hardware, and services. The Company specializes in five key markets. These are Healthcare, Government and Military, Law Enforcement, Legal Services, and Financial Services.
The above-mentioned Ecrypt One is a security-first, full service email system. It combines email server technology, with an array of security methods and solutions. Ecrypt One optimizes enterprise security through removing human vulnerabilities, and strengthens against data/device theft, leaks, as well as email-borne threats. In addition, it provides granular role based access controls for system administrators, and creates an innovative secure communications standard.
Ecrypt One is a direct replacement for traditional secured email systems comprising an email server, bundled with email security products and services. Ecrypt Technologies delivers it as a software appliance so one can install it on their preferred server hardware.
Today, Ecrypt Technologies announced that it entered into an agreement with Kaspersky Government Security Solutions (KGSS) to be the exclusive provider of its products and services to multiple U.S. federal government agencies through Ecrypt Technologies’ Marketing Alliance Program (MAP).
With this agreement, Ecrypt will be the exclusive global provider of KGSS’s cyber threat products and services to mutually-agreed upon U.S. government agencies. Products include KGSS’s Malware Indicators Database and Analysis System (MIDAS), Advanced Persistent Threat Analysis & Reporting platform, and assorted Intelligence Support Products.
Ecrypt Technologies, Inc. (ECRY), closed Thursday's trading session at $0.024, up 20.00%, on 3,447,920 volume with 155 trades. The average volume for the last 60 days is 1,550,701 and the stock's 52-week low/high is $0.0091/$0.59.
Medican Enterprises, Inc. (MDCN)
TopPennyStockMovers, PennyStocks24, and Pennybuster reported earlier on Medican Enterprises, Inc. (MDCN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Medican Enterprises, Inc. is a merchant bank and bio-pharmaceutical company in the emerging worldwide marijuana industry. Through its subsidiaries, it is looking to invest in its businesses associated with the growing, marketing, research and development (R&D), training, distribution and retail sale of medical and recreational marijuana in the U.S. and Canada. Medican Systems is the wholly-owned operating subsidiary of Medican Enterprises.
The Company is headquartered in Las Vegas, Nevada. It has extended the option to purchase two facilities in the Phoenix, Arizona area. The first facility located in Phoenix has a total retail footprint of 7,200 sq. ft. and is presently leased to a licensed medical marijuana dispensary. The other facility is a 66,000 square foot facility it is acquiring in Phoenix. It has received zoning approval. It is now zone compliant for the operation of legal medical marijuana businesses.
Medican’s emphasis is on cultivating strains of Cannabis with standardized potencies and verified purity: High THC / Low CBD; Medium THC / Low CBD; Medium THC / Medium CBD; and Low TCH / High CBD. Regarding Financial Consulting, Medican provides strategic planning, valuation, project debt, and corporate finance solutions to its joint venture (JV) Partners. This is to capitalize on the growing MMJ market and fund multiple facilities.
Its Medican Systems is the operating arm of Medican Enterprises’ Medical Marijuana Cultivation and Research Facilities. Medican Systems is working to become one of Canada’s first commercially Licensed Producers of Medical Marijuana (MMJ) under the new program Marijuana for Medical Purposes Regulation (MMPR).
Medican has formed Medican (US) Systems, Inc. This is a wholly-owned subsidiary established to pursue business activities in the U.S. medical marijuana and recreational marijuana sectors. Medican Enterprises has also formed a new wholly-owned subsidiary, Medican Nations, LLC. Medican Nations will focus on building strategic partnerships with Indian communities in the U.S. and Canada to create and build business solutions within the indoor gardening and marijuana industries.
Recently, Medican Enterprises announced that it closed on its acquisition of TWYNS, a company that provides branding services for enterprises in the Cannabidiol (CBD) business. The transaction is valued at roughly $1,000,000, all in stock and is expected to add approximately $400,000 to Medican Enterprises’ annual revenues. TWYNS offers licensing on commercial art work and its unique E-MC2 trademark to manufactures of supplements, salves, lotions, and edibles. In exchange, it will receive royalties from CBD wellness product sales globally.
Last week, Medican US, the U.S. subsidiary of Medican Enterprises announced that it executed and closed a lease agreement expanding its real estate and leasing business into California with Breeding Rare Cannabis Original Genetics, Inc. (BRCOG). The agreement specifies that BRCOG will lease the indoor warehouse, outdoor greenhouse and R&D property for $9000 USD per month for a minimum initial lease term of five years, and the first right of refusal for an additional five-year term. With this agreement, Medican Enterprises will provide lease improvements via financing, equipment and grow technologies.
Medican Enterprises, Inc. (MDCN), closed Thursday's trading session at $0.0012, even for the day, on 153,689,810 volume with 265 trades. The average volume for the last 60 days is 23,699,919 and the stock's 52-week low/high is $0.001/$21.50.
Omagine, Inc. (OMAG)
BUYINS.NET, PennyStocks24, Information Solutions Group, Agoracom, SmallCapVoice, and OnTheMar reported previously on Omagine, Inc. (OMAG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed Omagine, Inc. conducts all of its real-estate development, tourism, and entertainment business activities through either its 60 percent owned subsidiary Omagine LLC or its 100 percent owned subsidiary Journey of Light, Inc. Omagine’s emphasis is on real-estate, entertainment, and hospitality opportunities in the Middle East and North Africa (MENA Region). The Company is based in New York, New York.
Omagine has a family-oriented design and development predisposition. The Company employs this to make its properties tell true and entertaining stories about their surroundings and the world. Omagine’s developments seamlessly integrate entertainment with art, culture, science, and history.
The Company’s projects always include traditionally designed residential and commercial components. Nonetheless, the tourism components are thematically instilled with culturally aware and scientifically accurate entertainment experiences. All of the Company’s developments are historically faithful to their surroundings.
Omagine announced in October 2014 that Omagine LLC signed a Development Agreement (DA) with the Government of the Sultanate of Oman. Omagine organized Omagine LLC under the laws of Oman to design, develop, own, and operate a tourism and real-estate development project in Oman called the Omagine Project.
Omagine LLC owns the Omagine Project. The other Omagine LLC shareholders are the office of Royal Court Affairs (RCA), which owns 25 percent, and two subsidiaries of Consolidated Contractors International Company, SAL (CCIC), which collectively own 15 percent. The estimation is that the Omagine Project will cost approximately $2.5 billion to design, develop, and construct.
Omagine chooses unique locations, primarily in the MENA Region, which it designs and develops into distinctive tourism destinations, which have, as the Company indicates, a “high culture” flavor and a “pop culture” texture. Currently, Omagine focuses the majority of its efforts on the business of Omagine LLC and specifically on the Omagine Project.
In addition, Omagine has been holding discussions with Omani government officials pertaining to other projects in Oman. Furthermore, it has held initial discussions with government officials and business people in Libya regarding similar projects and other business opportunities in that country.
Further to the Omagine Project, it is planned to be an elegant integration of cultural, scientific, heritage, entertainment and residential components. This includes a high culture theme park containing seven pearl shaped (20 meter diameter) buildings (the Pearls) situated along an open air boardwalk with associated entertaining exhibitions; an amphitheater and stage; open space green landscaped areas; a canal; and an enclosed harbor and marina. It also includes boat slips and docking facilities; retail shops; an assortment of restaurants and cafes; entertainment venues; a five-star resort hotel; a four-star hotel; and possibly an additional three or four-star hotel; shopping and retail establishments integrated with the hotels; commercial office buildings; and more than 2000 residences to be developed for sale by Omagine LLC.
Omagine, Inc. (OMAG), closed Thursday's trading session at $1.60, up 1.91%, on 21,345 volume with 38 trades. The average volume for the last 60 days is 8,973 and the stock's 52-week low/high is $1.20/$3.94.
PositiveID Corp. (PSID)
Greenbackers, SmallCapVoice, TaglichBrothers, and OTPicks reported recently on PositiveID Corp. (PSID), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed PositiveID Corp. is a developer of biological detection and diagnostics solutions. The Company is a developer of biological detection systems for the Unites States’ homeland defense industry and rapid biological testing. PositiveID’s focus is on the development of microfluidic systems for the automated preparation of and performance of biological assays to detect biological threats at high-value locations and analyze samples in a medical environment. PositiveID is based in Delray Beach, Florida.
The Company acquired MicroFluidic Systems (MFS) in May of 2011. MFS specializes in the development and production of automated instruments for detecting and processing biological samples. Its core technology is used for airborne pathogen detection, rapid clinical diagnostics, as well as sample preparation applications.
Regarding Molecular Diagnostics, PositiveID’s products include M-BAND and Firefly. The Microfluidics-based Bioagent Networked Detector (M-BAND) developed by MFS is a bioaerosol monitor with fully integrated systems with sample collection, processing, and detection modules.
PositiveID is developing the Firefly Dx detection system. Firefly DX is its real-time, hand held, polymerase chain reaction (PCR) pathogen detection system. This system is a two-part device and it consists of a portable handheld instrument with wireless Bluetooth communication and disposable single-use cartridges containing all vital analytical elements.
PositiveID is developing Firefly Dx based on intellectual property (IP) and knowledge gained during years of development and $30 million of contract funding from the U.S. Department of Homeland Security for its M-BAND system. This system uses PCR for the identification of airborne bio-threats.
Last week, PositiveID announced that it successfully detected influenza on its Firefly Dx breadboard prototype PCR (polymerase chain reaction) pathogen detection system. Influenza is an RNA virus and necessitates a reverse transcription step to create cDNA before PCR being performed. The entire testing process was performed on the Firefly Dx breadboard, which is considerably faster than standard laboratory equipment and protocols, with results attained in minutes instead of hours or days.
PositiveID Corp. (PSID), closed Thursday's trading session at $0.0161, down 1.83%, on 2,050,517 volume with 101 trades. The average volume for the last 60 days is 3,855,102 and the stock's 52-week low/high is $0.014/$0.0845.
Cleartronic, Inc. (CLRI)
The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.085, up 13.33%, on 59,377 volume with 9 trades. The stock’s average daily volume over the past 60 days is 46,044, and its 52-week low/high is $0.04/$0.5499.
Cleartronic, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.
VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.
A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.
Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer
Cleartronic, Inc. Company Blog
Cleartronic, Inc. News:
Cleartronic, Inc. (CLRI) Begins Nationwide Retail Store Project
Cleartronic, Inc. (CLRI) Subsidiary Signs Agreement with Houston-Galveston Area Council
Cleartronic, Inc. (CLRI) on the "Your Monies Worth" Show
Galenfeha, Inc. (GLFH)
The QualityStocks Daily Newsletter would like to spotlight Galenfeha, Inc. (GLFH). Today, Galenfeha, Inc. closed trading at $0.2784, up 3.73%, on 3,770 volume with 2 trades. The stock’s average daily volume over the past 60 days is 30,487, and its 52-week low/high is $0.1011/$4.00.
Galenfeha, Inc. (GLFH) is an engineering, product development, and manufacturing company that provides innovative solutions for oil and natural gas production, as well as stored energy products across a number of different industries. The company provides these products and services through its stored energy and oil & gas division.
Through its stored energy division, Galenfeha offers one of the most powerful, environmentally friendly battery systems in the market. The batteries have onboard computers, are inherently safe, internally temperature regulated, have optional GPS monitoring capabilities, offer significant weight reduction of up to 50%, and are engineered specifically for each type of application. Features include 100% “green” chemistry, RoHS compliancy, and active short circuit protection control.
Through its oil and gas division, the company offers chemical injection pumps that merge the perceived benefits of a hybrid, electric over pneumatic system. Galenfeha management believes the combination of the two parameter control systems represents a measurable shift in efficiency, reliability, cost management, and profitability to individual well locations as well as entire production fields. The combined technologies have demonstrated increased chemical injection accuracy, reducing chemical contamination in the production process while controlling cost and waste.
The company’s unwavering dedication is to continuously develop products that perform better than conventional solutions while also reducing environmental impact. Leveraging the management team’s wealth of resources and relationships, Galenfeha is well positioned for continued growth as the company aims to expand in both the stored energy and oil & gas industries. Disclaimer
Galenfeha, Inc. Company Blog
Galenfeha, Inc. News:
Galenfeha, Inc. Announces Engagement of QualityStocks Investor Relations Services
GALENFEHA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Galenfeha, Inc. Completes Field Testing, Begins Production and Shipping of New Battery System
Car Monkeys Group (CKMY)
The QualityStocks Daily Newsletter would like to spotlight Car Monkeys Group (CKMY). Today, Car Monkeys Group closed trading at $0.131, even for the day, on 7 volume with 1 trade. The stock’s average daily volume over the past 60 days is 7,567, and its 52-week low/high is $0.05/$5.00.
Car Monkeys Group (CKMY), via CarMonkeys.com, is one of the largest and fastest growing online cars, vans and SUV parts distributors in the United States. Founded in 2010, the Wyckoff, New Jersey-based company formerly was known as Delaine Corporation and changed its name to Car Monkeys Group in February 2015.
With access to hundreds of thousands of parts, Car Monkeys sells used, high-quality, low-mileage automotive parts to consumers, retailers, truck and car fleet owners and auto repair facilities looking for a wide range of vehicle makes and models. Customers have access to a Part Finder section that helps them easily navigate and quickly locate the right parts they need.
Striving to provide customers a quick, hassle-free and convenient shopping experience, all parts ordered through CarMonkeys.com ship from one of the company’s numerous distributors and auto dismantling centers straight to the customer or their mechanic. Advantages such as a five-year unlimited mileage warranty, zero shipping costs, and a generous return policy further contribute to the increasing popularity of the Car Monkeys brand.
Automotive recycling plays a substantial role in the preservation of natural resources and reduction of demand for landfill space. According to the Automotive Recyclers Association, approximately 95% of vehicles retired from use are processed for recycling, saving an estimated 85 million barrels of oil that would have been used to manufacture new or replacement parts. As a rapidly growing and trusted automotive recycling company, Car Monkeys is positioned as a leading player in the broader $22 billion North American automotive recycling industry. Disclaimer
Car Monkeys Group Company Blog
Car Monkeys Group News:
Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
Car Monkeys Group (CKMY) is “One to Watch”
Car Monkeys Group (CKMY) Continues Growth as one of the Country’s Largest Online Automobile Parts Distributors
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.05, up 1.01%, on 193,654 volume with 26 trades. The stock’s average daily volume over the past 60 days is 800,725, and its 52-week low/high is $0.045/$0.155.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Present at International Society for Cellular Therapy Annual Meeting
International Stem Cell Corporation Announces 2015 First Quarter Results
International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $10.00, even for the day, on 621 volume with 3 trades. The stock’s average daily volume over the past 60 days is 430, and its 52-week low/high is $3.16/$15.00.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
Today's Top 3
Wall Street Mover
Daily Stock Motion
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
- Cleartronic, Inc. (CLRI) Begins Nationwide Retail Store Project
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Set for Relaunch With New Branding
- Galenfeha, Inc. (GLFH) Completes Field Testing, Begins Production and Shipping of New Battery System
- Growblox Sciences, Inc. (GBLX) Announces Commercialization Initiative and Financing
- IFAN Financial, Inc. (IFAN) $2.5 Million Sea Otter Global Ventures Financing Progresses
- International Stem Cell Corp. (ISCO) to Present at International Society for Cellular Therapy Annual Meeting
- Loans4Less.com Inc. (LFLS) Enters into an Acquisition Agreement with 321LEND
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International
- One World Holdings, Inc. (OWOO) Raises Capital to Fund National Expansion and Convertible Note Elimination
- Pure Hospitality Solutions, Inc. (PNOW) Files First Quarter Disclosures
- Save The World Air, Inc. (ZERO) Congratulates Pipeline Research Council International on New Technology Development Center
- View Systems, Inc. (VSYM) Continues to Install Its Proprietary Scanning Systems Nationwide
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors